Skip to main content

Table 2 Baseline characteristics of participants

From: Effects of a pharmaceutical care intervention on clinical outcomes and patient adherence in coronary heart disease: the MIMeRiC randomized controlled trial

 

Intervention group (n = 159)

Control group (n = 157)

P

Age (years), mean ± SD

68.3 (8.9)

68.6 (8.6)

.744

Male, n (%)

116 (73.0)

119 (75.8)

.563

Born outside Sweden, n (%)

10 (6.3)

11 (7.0)

.798

Married or cohabitating, n (%)

126 (79.2)

122 (78.2)

.737

Educational level, n (%)

  

.750

 Comprehensive school

56 (35.2)

60 (38.2)

 

 Upper secondary school

43 (27.0)

37 (23.6)

 

 Bachelor’s/Master’s degree

60 (37.7)

60 (38.2)

 

Type of CHD, n (%)

  

.834

 STEMI

46 (28.9)

48 (30.6)

 

 Non-STEMI

48 (30.2)

43 (27.4)

 

 Unstable angina

17 (10.7)

18 (11.5)

 

 Chronic angina

32 (20.1)

37 (23.6)

 

 Other reason for PCI

15 (9.4)

10 (6.4)

 

History of CHD, n (%)

47 (29.6)

45 (28.7)

.919

Unplanned healthcare contact for CVD, preceding year, n (%)

27 (17.0)

20 (12.7)

.289

Coronary intervention, n (%)

  

.459

 PCI with DES

126 (79.7)

110 (72.8)

 

 Other PCI

12 (7.6)

12 (7.9)

 

 CABG

10 (6.3)

15 (9.9)

 

 None

10 (6.3)

14 (9.3)

 

Comorbidities, n (%)

   

 Hypertension

79 (48.4)

74 (49.0)

.910

 Other CVD

22 (13.8)

17 (10.8)

.392

 Diabetes

23 (14.5)

20 (12.7)

.622

 Other comorbidities

60 (37.7)

70 (44.6)

.303

 No comorbidities

35 (22.0)

33 (21.0)

.830

Clinical risk factors, n (%)

   

 Smoking

11 (8.0)

17 (12.6)

.080

 Smoking eligible participants, n

137

135

 

 Mean LDL-C, mmol/L (SD)

2.2 (0.8)

2.3 (0.8)

.909

 LDL -C, treatment target reached, n (%)

55 (39.6)

58 (41.7)

.714

 LDL-C eligible participants, n

139

139

 

 Mean SBP mm Hg (SD)

139.5 (20.6)

138.1 (19.6)

.526

 SBP, treatment target reached, n (%)

79 (52.3)

90 (58.1)

.312

 Mean DBP, mm Hg (SD)

76.1 (11.6)

75.1 (11.7)

.460

 BP eligible participants, n

151

155

 

Number of drugs prescribed per participant

   

 For regular use, mean (SD)

7.2 (2.4)

7.3 (2.3)

.871

 As needed, mean (SD)

2.1 (1.2)

2.1 (1.3)

.899

Self-reported adherencea

   

 MMAS-8 score (SD)

7.5 (1.2)

7.5 (1.0)

.889

 MMAS-8 medium or high adherence, n (%)

132 (93.0)

137 (91.9)

.744

 MMAS-8 eligible participants, n*

142

149

 

Beliefs about medicines

   

 Mean Necessity score (SD)

19.0 (3.1)

19.0 (3.1)

.913

 Mean Concern score (SD)

13.0 (4.9)

13.1 (5.1)

.884

 Mean Necessity-Concerns differential (SD)

6.0 (5.7)

5.9 (6.3)

.964

BMQ-S attitudinal category

  

.359

 Accepting, n (%)

79 (51.0)

82 (53.2)

 

 Ambivalent, n (%)

54 (34.8)

50 (32.5)

 

 Indifferent, n (%)

11 (7.1)

7 (4.5)

 

 Skeptical, n (%)

8 (5.2)

15 (9.5)

 

HeartQol score

   

 Mean HeartQoL physical (SD)

2.2 (0.8)

2.2 (0.7)

.926

 Mean HeartQoL emotional (SD)

2.4 (0.7)

2.3 (0.8)

.178

Mean number of days from discharge to randomization (SD)

116.4 (37.7)

122.5 (51.0)

.226

  1. BP, blood pressure; BMQ-S, Beliefs about medicines questionnaire Specific; CABG, Coronary artery by-pass grafting; CHD, coronary heart disease; CVD, cardiovascular disease; DES, drug-eluting stent; DBP, diastolic blood pressure; HeartQoL, health-related quality of life; LDL-C, low-density lipoprotein cholesterol; MMAS-8, Morisky 8-item adherence scale; n, number; PCI, percutaneous coronary intervention; SBP, systolic blood pressure; STEMI, ST-elevation myocardial infarction
  2. *This questionnaire was only to be filled in by those with a prescription for a cholesterol-lowering drug
  3. aThe use of MMAS diagnostic adherence assessment instrument is protected by US copyrighted and trademarked laws. Permission for use is required. A license is available from—MORISKY MEDICATION ADHERENCE RESEARCH, LLC., Donald E. Morisky, ScD, ScM, MSPH, MMAR, LLC, 294 Lindura Ct., Las Vegas, NV 89138; dmorisky@gmail.com